Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.

The purpose of this article is to provide a review of the current knowledge and opinions about the epidemiology, clinical findings (including sequelae), diagnosis, treatment and monitoring of equine pituitary pars intermedia dysfunction, particularly in the Australian context. This information and the recommendations provided will assist practitioners in making informed decisions regarding the diagnosis and management of this disorder.

Seroprevalence and associated risk factors of mosquito-borne alphaviruses in horses in northern Queensland.

OBJECTIVE: To investigate the seroprevalence and associated risk factors of alphaviruses (Ross River virus (RRV), Barmah Forest virus (BFV) and Whataroa virus (WHAV)) in northern Queensland horses. METHODS: A cross-sectional study of alphavirus antibodies in horses (n = 287) from 147 properties in northern Queensland from September 2013 to June 2014 was conducted. Owners of sampled horses were interviewed on potential risk factors. Data were analysed for associations using multivariable logistic regression. RESULTS: Antibody titres for RRV were demonstrated in samples from 134 properties (91%; 95% confidence interval (CI) 87-96%); 22 properties (15%) had BFV reactors (95% CI 12-18%) and 2 properties (1.4%) had WHAV reactors (95% CI -0.5-3.2%). The highest seroprevalence of RRV was in the Townsville-Burdekin region (93%; 95% CI 90-96%) followed by the Mackay-Whitsunday (90%; 95% CI 88-98%) and Far North Coast-Tableland (82%; 95% CI 74-90%) regions. No association (P ≤ 0.05) could be shown between any of the viruses and age groups, sexes, annual average temperature, degree of rainfall or proximity to wet environments. An association with reported large numbers of mosquitoes was seen for RRV but not BFV. A significant association between properties in close proximity to poultry and pigs was shown for BFV. CONCLUSION: RRV is endemic within the horse population of northern Queensland, but horses exhibit few clinical signs and could play a role as amplifying hosts in the tropics. Exposure of horses to BFV is significant in northern Queensland and it should be considered a differential diagnosis for RRV. WHAV warrants further study.

Virus-neutralising antibody responses in horses following vaccination with Equivac® HeV: a field study.

OBJECTIVE: To determine the antibody responses to a commercial Hendra virus vaccine (Equivac® HeV) in a field environment. METHODS: A group of 61 horses received a primary vaccination course comprising two doses administered 3-6 weeks apart (V1, V2) and a 3rd dose (V3) given 6 months after the second. This was followed by booster vaccinations at 12 monthly intervals (V4, V5). Antibody titres were assessed using a virus-neutralisation test. RESULTS: Neutralising antibodies against HeV were not detected prior to vaccination. Antibodies were detected in 54/57 horses at 3 weeks after V1 and 51/51 had titres ≥ 32 at 8 weeks after V2. At 6 months after V2, antibody titres decreased in most (31/34) horses and were not detected in three horses. A rapid increase in antibody titres was recorded in 35/36 horses at 1 week following V3. By the first annual booster vaccination (V4), antibodies were still detectable in 29/29 horses, although titres had decreased; in 26/29 horses, titres remained ≥ 32. All horses showed an increase in antibody titres after V4. There was no statistically significant increase in mean antibody titre after V5, compared with after V4. CONCLUSION: Horses administered Equivac® HeV, using a primary vaccination course followed by annual booster vaccinations, mounted an effective secondary immune response and acquired antibody responses that were consistent with protective immunity against HeV in the form of virus-neutralising antibodies. No adverse events were observed after vaccine administration.